Almirall, S.A. announces that Sativex® is now available to health professionals and patients in the Spanish hospital pharmacies. It is the first specific treatment for spasticity in MS patients who have not responded adequately to other treatments. Sativex® is administered as oromucosal spray enabling flexible dosage, which is particularly appropriate given the variable nature ofspasticity and MS itself.
Evidence from clinical trials shows that Sativex® has a positive impact on spasticity, sleep quality and mobility and enables patients to carry out everyday tasks such as getting up, getting dressed or washed. This affords patients greater independence and reduces the frequency of spasms. It is estimated that in Spain there are around 40,000 people with MS and up to 75% of them suffer from spasticity in the course of their disease.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1814